북미의 생물 제제 시장 : 예측 - 지역별 분석 - 제품, 용도, 공급원, 제조별

The North America biologics market was valued at US$ 230,256.1 million in 2023 and is expected to reach US$ 888,880.0 million by 2031; it is estimated to register a CAGR of 18.4% from 2023 to 2031.

Increasing Prevalence of Chronic Diseases Fuels North America Biologics Market

According to a study titled "Chronic Disease: A Bio-Logical Approach," published in Ellerston Capital Limited, 41 million people worldwide die from chronic diseases every year, accounting for 74% of all deaths worldwide. Cancer was responsible for almost 10 million deaths in 2020, i.e., 1 in every 6 deaths. According to GLOBOCAN, 19.3 million cancer cases were registered worldwide in 2020, and the number is estimated to rise to 24.6 million by 2030. In addition, the prevalence of autoimmune diseases increases annually by 3-9%. The number of Alzheimer's disease cases is expected to reach 78 million by 2030 and 139 million by 2050. According to the World Health Organization (WHO), every year, ~17 million people across the world succumb to death due to noncommunicable diseases before the age of 70.

Biologics such as antibodies and vaccines offer more targeted treatment because they are designed to interact with the immune system in specific ways to deliver a therapeutic or prophylactic effect. Biological drugs have the promising potential to treat a few chronic autoimmune diseases by blocking the overactive components (proteins in many cases) of the immune system, which damage joints, skin, and other body parts. The treatment of cancer with biologics involves using the body's immune cells to kill cancerous cells; cytokines such as interferons, interleukins, and monoclonal antibodies (mAbs) are the most commonly used biologic therapies employed to treat cancer. Anti-amyloid mAbs have also shown promising therapeutic effects in clinical studies conducted on Alzheimer's disease patients. Chronic diseases such as ulcerative colitis and Crohn's disease include recurring episodes of inflammation of the mucosal layer of the colon. The US Food and Drug Administration has approved a few biological drugs for the treatment of Crohn's disease; these include infliximab, adalimumab, and natalizumab. Further, biological disease-modifying antirheumatic drugs are one of the major approaches to treating rheumatoid arthritis. With the shift in doctors' and patients' preference from conventional to aggressive approaches, the demand for biologics in the treatment of rheumatoid arthritis is also on the rise. Therapeutics use are partially or fully humanized proteins targeting different immune response pathways. Therefore, the increasing prevalence of chronic diseases drives the growth of the biologics market.

North America Biologics Market Overview

North America holds the largest share of the biologics market in terms of revenue. Market growth in this region is attributed to the presence of key biologics manufacturing players and the increasing spending on R and D. According to an article published in the JAMA Network, biologics R and D spending accounted for 37% of total R and D spending in the US. The number of prescriptions written for biologics and investments in the development of targeted drugs are on the rise in the country. Additionally, the approval of several novel biological drugs such as antisense, gene therapy, and RNAi therapeutics is expected to further drive the market growth. As per an article published by the National Center for Biotechnology Information (NCBI), the country recorded historically the highest percentage of biologics approvals in 2022, i.e., 40%, which indicates the stability of biologics in pharmaceutical applications. Moreover, this category of drugs accounts for 30% of the total drug approvals. In May 2024, Biocon Biologics Ltd (BBL) received FDA approval for YESAFILI (aflibercept) as the first biological alternative to Eylea. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor used to treat several different types of ophthalmology conditions.

North America Biologics Market Revenue and Forecast to 2031 (US$ Million)

North America Biologics Market Segmentation

The North America biologics market is categorized into product, application, source, manufacturing, and country.

Based on product, the North America biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of application, the North America biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.

By source, the North America biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.

Based on manufacturing, the North America biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.

In terms of country, the North America biologics market is segmented into the US, Canada, and Mexico. The US dominated the North America biologics market share in 2023.

AbbVie Inc, Pfizer Inc, Samsung Biologics Co Ltd, ADMA Biologics, Inc., Wuxi Biologics Inc, Catalent Inc, AGC Biologics AS, AstraZeneca Plc, Amgen Inc, Nitto Avecia, and Quality Assistance s.a. are some of the leading companies operating in the North America biologics market.

Table Of Contents

1. Introduction

• 1.1 Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights
• 2.2 Market Attractiveness

3. Research Methodology

• 3.1 Secondary Research
• 3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macroeconomic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country-level data:

4. North America Biologics Market - Key Market Dynamics

• 4.1 Market Drivers
  • 4.1.1 Increasing Prevalence of Chronic Diseases
  • 4.1.2 Preference for Outsourcing Manufacturing Operations
• 4.2 Market Restraints
  • 4.2.1 High Cost of Biologics
• 4.3 Market Opportunities
  • 4.3.1 Gene and Cell Therapy Advancements in Biologics
• 4.4 Future Trends
  • 4.4.1 Strategic Initiatives by Companies
• 4.5 Impact of Drivers and Restraints:

5. Biologics Market - North America Analysis

• 5.1 North America Biologics Market Revenue (US$ Million), 2021-2031
• 5.2 North America Biologics Market Forecast Analysis

6. North America Biologics Market Analysis - by Product

• 6.1 Monoclonal Antibodies
  • 6.1.1 Overview
  • 6.1.2 Monoclonal Antibodies: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.2 Vaccine
  • 6.2.1 Overview
  • 6.2.2 Vaccine: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.3 Recombinant Hormones/Proteins
  • 6.3.1 Overview
  • 6.3.2 Recombinant Hormones/Proteins: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.4 Cell and Gene Therapy
  • 6.4.1 Overview
  • 6.4.2 Cell and Gene Therapy: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.5 Others
  • 6.5.1 Overview
  • 6.5.2 Others: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. North America Biologics Market Analysis - by Application

• 7.1 Cancer
  • 7.1.1 Overview
  • 7.1.2 Cancer: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.2 Infectious Diseases
  • 7.2.1 Overview
  • 7.2.2 Infectious Diseases: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.3 Autoimmune Diseases
  • 7.3.1 Overview
  • 7.3.2 Autoimmune Diseases: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.4 Others
  • 7.4.1 Overview
  • 7.4.2 Others: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. North America Biologics Market Analysis - by Source

• 8.1 Mammalian
  • 8.1.1 Overview
  • 8.1.2 Mammalian: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 8.2 Microbial
  • 8.2.1 Overview
  • 8.2.2 Microbial: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. North America Biologics Market Analysis - by Manufacturing

• 9.1 Outsourced
  • 9.1.1 Overview
  • 9.1.2 Outsourced: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 9.2 In-house
  • 9.2.1 Overview
  • 9.2.2 In-house: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. North America Biologics Market - Country Analysis

• 10.1 North America
  • 10.1.1 North America Biologics Market - Revenue and Forecast Analysis - by Country
    • 10.1.1.1 North America Biologics Market - Revenue and Forecast Analysis - by Country
    • 10.1.1.2 United States: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.2.1 United States: North America Biologics Market Share - by Product
      • 10.1.1.2.2 United States: North America Biologics Market Share - by Application
      • 10.1.1.2.3 United States: North America Biologics Market Share - by Source
      • 10.1.1.2.4 United States: North America Biologics Market Share - by Manufacturing
    • 10.1.1.3 Canada: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.3.1 Canada: North America Biologics Market Share - by Product
      • 10.1.1.3.2 Canada: North America Biologics Market Share - by Application
      • 10.1.1.3.3 Canada: North America Biologics Market Share - by Source
      • 10.1.1.3.4 Canada: North America Biologics Market Share - by Manufacturing
    • 10.1.1.4 Mexico: North America Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.4.1 Mexico: North America Biologics Market Share - by Product
      • 10.1.1.4.2 Mexico: North America Biologics Market Share - by Application
      • 10.1.1.4.3 Mexico: North America Biologics Market Share - by Source
      • 10.1.1.4.4 Mexico: North America Biologics Market Share - by Manufacturing

11. Industry Landscape

• 11.1 Overview
• 11.2 Market Initiative
• 11.3 Partnerships and Collaborations
• 11.4 Other Developments

12. Company Profiles

• 12.1 AbbVie Inc
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Pfizer Inc
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 Samsung Biologics Co Ltd
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4 ADMA Biologics, Inc.
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
• 12.5 WuXi Biologics Inc
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
• 12.6 Catalent Inc
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments
• 12.7 AGC Biologics AS
  • 12.7.1 Key Facts
  • 12.7.2 Business Description
  • 12.7.3 Products and Services
  • 12.7.4 Financial Overview
  • 12.7.5 SWOT Analysis
  • 12.7.6 Key Developments
• 12.8 AstraZeneca Plc
  • 12.8.1 Key Facts
  • 12.8.2 Business Description
  • 12.8.3 Products and Services
  • 12.8.4 Financial Overview
  • 12.8.5 SWOT Analysis
  • 12.8.6 Key Developments
• 12.9 Amgen Inc
  • 12.9.1 Key Facts
  • 12.9.2 Business Description
  • 12.9.3 Products and Services
  • 12.9.4 Financial Overview
  • 12.9.5 SWOT Analysis
  • 12.9.6 Key Developments
• 12.10 Nitto Avecia
  • 12.10.1 Key Facts
  • 12.10.2 Business Description
  • 12.10.3 Products and Services
  • 12.10.4 Financial Overview
  • 12.10.5 SWOT Analysis
  • 12.10.6 Key Developments
• 12.11 Quality Assistance s.a.
  • 12.11.1 Key Facts
  • 12.11.2 Business Description
  • 12.11.3 Products and Services
  • 12.11.4 Financial Overview
  • 12.11.5 SWOT Analysis
  • 12.11.6 Key Developments

13. Appendix

• 13.1 About Us